A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Newly Diagnosed AML With FLT3 Activating Mutations
Interventions
DRUG

crenolanib

DRUG

cytarabine

DRUG

daunorubicin

DRUG

idarubicin

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medical College, New York

14263

Roswell Park Cancer Institute, Buffalo

44195

Cleveland Clinic, Cleveland

52242

University of Iowa Hospitals and Clinics, Iowa City

75390

University of Texas Southwestern Medical Center, Dallas

91010

City of Hope Medical Center, Duarte

98195

Fred Hutchinson Cancer Research Center, Seattle

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Arog Pharmaceuticals, Inc.

INDUSTRY